Leading the Way in Life Science Technologies

GEN Exclusives

More »

March 1, Vol. 29, No. 5

  • Feature Articles

    • China Stays Committed to Biodevelopment
    • Zhu Shen
    • The global economic meltdown has finally slowed the unparalleled engine of growth responsible for China’s 30-year economic miracle Chinese GDP, which has been growing at an annual rate of 10–15%, is projected to grow at only 8% or less in ... more »
    • Researchers Map Neanderthal Genome
    • Scientists from the Max Planck Institute for Evolutionary Anthropology and 454 Life Sciences reported  completion of the 1X draft sequence of the Neanderthal genome The team, which began the project in July 2006, also announced the completion of the 18-fold ... more »
    • Revitalizing Surface Plasmon Resonance
    • Diana Gitig, Ph.D.
    • Surface plasmon resonance, or SPR, is used to measure changes in molecular weight Thus, it has  long been used to study protein-protein interactions by registering the association and dissociation of a ligand (prey) binding to an immobilized protein (bait) ... more »
    • Review: LabAuto Product Introductions
    • Ilene Schneider
    • When times get tough, manufacturers of laboratory automation equipment rely on out-of-the-box thinking to provide greater economy and efficiency for life scientists  “LabAutomation,” held in Palm Springs the last week in January, showcased more than 4,000 hardware and software advances, ... more »
    • Quality Makes a Difference in RNA Prep
    • K. John Morrow Jr.
    • In recent years, drug discovery has become a search for targets that take the form of gene-expression differences between normal and disease states One of the leading approaches has been based on building gene-expression profiles derived from microarray analysis In ... more »
    • DNA Vaccines Inch Toward Human Use
    • Gail Dutton
    • A DNA vaccine targeting West Nile virus in equines was launched in December by the Fort Dodge Animal Health division of Wyeth That vaccine was reportedly the first DNA vaccine for any species to be registered with a government regulatory ... more »
    • CMOs Hold Their Ground in Troubled Times
    • Angelo DePalma
    • Despite the economic downturn, contract biomanufacturing remains strong and vibrant Contract manufacturing organizations (CMOs) continue to provide specialized research, development, and manufacturing services for large, small, and virtual biotechnology companies alike... more »
    • Quest for Fully Disposable Process Stream
    • Vicki Glaser
    • The disposable bioprocessing market, which began with plastic bags designed for buffer preparation and quickly evolved to disposable bioreactor bags on rocking platforms, has blossomed into a range of products for cell culture and the processes upstream and downstream of ... more »
    • Personalized Medicine Grows in Fits and Starts
    • Lloyd Dunlap
    • The road to personalized medicine depends on development of biomarker assays that can reliably—with ultrahigh sensitivity and specificity—identify what is going on in the patient’s system At CHI’s “Biomarker Assay Development” conference held recently in San Diego, several presentations focused ... more »
    • Clinical Proteomics Heads Into Real World
    • N. Anderson
    • Given that proteins are the primary working parts of cells, it seems self-evident that proteomics should yield abundant clues to disease mechanisms, as well as numerous clinically useful biomarkers Biomarkers in readily accessible bodily fluids such as plasma, in particular, ... more »
    • Making the Most of Pre-IDE Meetings
    • Jeffrey N. Gibbs
    • In order to sell diagnostic devices in the US, in vitro diagnostic (IVD) manufacturers need to get marketing authorization from FDA That raises an obvious question: How does a company know what data to submit and which regulatory pathway to ... more »
  • Columns

    • Stem Cell Funding Roadblock
    • Bernard Siegel
    • When President Bush assumed office, the human embryonic stem cell revolution was primed to launch The outgoing Clinton administration directed the NIH to prepare comprehensive rules to govern the nascent field of discovery, with funding to follow Eight years later, ... more »
    • Impact of Risk Mitigation on Deal Market
    • Mark Metcalf
    • Despite a volatile and uncertain economy, 2009 may be an active year for deals between pharmaceutical and biotech companies A number of factors, including biotech companies’ difficulty in securing funding and the strategic needs of pharmaceutical companies, are converging to ... more »
    • Agilent Expands Its Capabilities in Robotics
    • Carol Potera
    • In December 2007, Agilent Technologies acquired Velocity11, a supplier of automated liquid-handling and laboratory robotic instruments for the life science market “Our goal in the life sciences is to put together workflows that solve customer problems,” says Nick Roelofs, vp ... more »